Want to join the conversation?
Mark Schoenebaum of Evercore ISI asks what is $AMGN's appetite for an at-risk Humira biosimilar launch. CEO Bob Bradway said the company is not going to comment on its launch plans for Humira. He added that the next step is for $AMGN to get a regulatory approval for its molecule and that is what the company is focused on securing.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?